Steven E. Lufkin

Amministratore Delegato presso SeLux Diagnostics, Inc.

61 anni

Health Technology

Profilo

Steven E.
Lufkin is currently the Chief Executive Officer & Director at SeLux Diagnostics, Inc. He was previously the General Manager at ERBA Diagnostics, Inc. for a brief period in 2010.

Posizioni attive di Steven E. Lufkin

Società	Posizione	Inizio
SeLux Diagnostics, Inc. SeLux Diagnostics, Inc. Medical SpecialtiesHealth Technology SeLux Diagnostics, Inc. develops universal synthetic amplifier technology equipment. The firm offers Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. The company was founded by Eric Stern and Aleksander Vacic in 2014 and is headquartered in Charlestown, MA.	Amministratore Delegato	01/01/2017

Tutte le posizioni attive di Steven E. Lufkin

Precedenti posizioni note di Steven E. Lufkin

Società	Posizione	Fine
ERBA DIAGNOSTICS, INC.	Corporate Officer/Principal	30/09/2010

Vedi nel dettaglio l'esperienza di Steven E. Lufkin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Steven E. Lufkin

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
ERBA Diagnostics, Inc. ERBA Diagnostics, Inc. Medical SpecialtiesHealth Technology ERBA Diagnostics, Inc. was engaged in manufacturing and marketing of proprietary diagnostic reagents, test kits and instrumentation in the areas of autoimmune, chemistry, hematology, diabetes, and infectious diseases. The company was founded on March 14, 2001 and was headquartered in Miami Lakes, FL.	Health Technology
SeLux Diagnostics, Inc. SeLux Diagnostics, Inc. Medical SpecialtiesHealth Technology SeLux Diagnostics, Inc. develops universal synthetic amplifier technology equipment. The firm offers Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. The company was founded by Eric Stern and Aleksander Vacic in 2014 and is headquartered in Charlestown, MA.	Health Technology